Weed (BUDZ) Research & Development (2010 - 2012)

Weed (BUDZ) posted quarterly Research & Development of $1359.0 for Q1 2012, down 89.51% quarter-over-quarter from $12950.0 in Q4 2011.

Weed (BUDZ) Research & Development (2010 - 2012) Analysis & Trends

Weed's Research & Development history runs 3 years deep, the most recent figure standing at $1359.0 for Q1 2012.

In Q1 2012, Research & Development changed N/A year-over-year to $1359.0; the TTM figure through Mar 2012 stood at $30369.0 (changed N/A YoY), while the FY2011 annual figure was $12950.0, down 67.78% from the prior year.
Research & Development for Q1 2012 stood at $1359.0, down from $12950.0 in the prior quarter.
The five-year high for Research & Development was $40187.0 in Q4 2010, with the low at $1359.0 in Q1 2012.
The 3-year median for Research & Development is $14505.0 (2011), against an average of $17639.0.
Peak annual rise in Research & Development reached 67.78% in 2011, while the deepest fall reached 67.78% in 2011.
Weed's Research & Development stood at $40187.0 in 2010, then slumped by 67.78% to $12950.0 in 2011, then plunged by 89.51% to $1359.0 in 2012.
Business Quant data shows BUDZ's Research & Development at $1359.0 in Q1 2012, $12950.0 in Q4 2011, and $16060.0 in Q3 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	970.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	-1.05 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	146.30 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	248.30 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	326.70 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	92.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Weed	2.88 Mn	2.88 Mn	-	-

Download Data